Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells" [Pharmacol. Res. 70 (2013) 90-101].

Pharmacological research·2026
Same author

Retraction notice to "Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation" [Biochem. Pharmacol. 82 (2011) 524-534].

Biochemical pharmacology·2026
Same author

Synergistic effect of combined hyperthermia and radiotherapy mediated by AQP5 reduction in pancreatic cancer.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2026
Same author

Adenylate kinase 4 promotes radioresistance by suppressing radiation-induced ferroptosis through metabolic regulation in glioblastoma.

Apoptosis : an international journal on programmed cell death·2026
Same author

Epigenetic Silencing of Primary Cilia Genes by PRAME and ETS2 in Melanoma Cells.

Journal of cellular physiology·2026
Same author

Retraction: PAK3 downregulation induces cognitive impairment following cranial irradiation.

eLife·2026

Related Experiment Video

Updated: Jan 11, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K

NanoBRET-Based Biosensor for High-Throughput Screening of RAB11A-FIP2 Interaction Inhibitors.

Gaeun Yoo1, Hyunkoo Kang2, Haksoo Lee1

  • 1Department of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.

Analytical Chemistry
|November 19, 2025
PubMed
Summary

We developed a novel NanoBRET biosensor to screen for small molecules that inhibit protein-protein interactions (PPIs) crucial for cancer metabolism. This platform identified inhibitors disrupting RAB11A-FIP2 binding, impacting glucose transport in glioblastoma.

More Related Videos

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.5K
A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

10.3K

Related Experiment Videos

Last Updated: Jan 11, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.5K
A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

10.3K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Protein-protein interactions (PPIs) are vital cellular regulators and therapeutic targets.
  • Current PPI drug discovery methods lack cellular context.
  • RAB11A regulates glucose transporter trafficking, a key metabolic process in glioblastoma.

Purpose of the Study:

  • To develop a NanoBRET-based biosensor for live-cell detection of PPIs.
  • To screen small molecules for inhibitors of the RAB11A-FIP2 interaction.
  • To evaluate the therapeutic potential of identified inhibitors in glioblastoma.

Main Methods:

  • Developed a NanoBRET biosensor for RAB11A activation.
  • Screened 7040 small molecules using the biosensor.
  • Assessed the impact of inhibitors on RAB11A-FIP2 binding and GLUT3 trafficking.

Main Results:

  • Identified potent small molecule inhibitors that disrupt RAB11A-FIP2 interaction.
  • Demonstrated that inhibition attenuates GLUT3 trafficking and glucose metabolism in glioblastoma.
  • Validated three candidate molecules for their ability to interfere with RAB11A activation and GLUT3 trafficking.

Conclusions:

  • The NanoBRET biosensor is a robust platform for high-throughput screening of PPI inhibitors.
  • Targeting the RAB11A-FIP2 axis offers a promising strategy for glioblastoma metabolic intervention.
  • Identified small molecules hold potential as novel therapeutics for metabolic regulation in cancer.